Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 3, 2003, Pages 641-648

  Naidu, Pattipati S ^a   Singh, Amanpreet ^a   Kaur, Pushpinder ^b   Sandhir, Rajat ^b   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Haloperidol; Melatonin; Oxidative stress; Tardive dyskinesia; VCMs

Indexed keywords

ANTIOXIDANT; CATALASE; GLUTATHIONE; HALOPERIDOL; LIPID; MELATONIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; ENZYME ASSAY; FOREBRAIN; LIPID PEROXIDATION; LONG TERM EXPOSURE; MALE; MASTICATION; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; RAT; TONGUE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FREE RADICALS; HALOPERIDOL; LIPID PEROXIDATION; MALE; MELATONIN; PROSENCEPHALON; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0037304409     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01051-1     Document Type: Article

References (75)

1. Abilio V.A. Jr., Vera J.A., Ferreira L.S., Duarte C.R., Carvalho R.C., Grassl C.et al. Effect of melatonin on orofacial movements. Psychopharmacology. 161:2002;340-347.
2. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats implications for tardive dyskinesia? Prog. Neurobiol. 61:2000;525-541.
3. Aruoma O.I. Free radicals: dietary advantages and disadvantages. Scandalios J.C. Oxidative stress and the molecular biology of antioxidant defenses. 1997;841-860 Cold Spring Harbor Laboratory Press, Boston.
4. Balijepalli S., Kenchappa R.S., Boyd M.R., Ravindranath V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem. Int. 38:2001;425-435.
5. Bandyopadhyay D., Biswas K., Bandyopadhyay U., Reiter R.J., Banerjee R.K. Melatonin protects against stress-induced gastric lesions by scavenging hydroxyl radical. J. Pineal Res. 29:2000;143-151.
6. Barlow-Walden L.R., Reiter R.J., Abe M., Pablos M., Menendez-Pelaes A., Chenm L.D.et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 26:1995;497-502.
7. Bromme H.J., Morke W., Peschke E., Ebelt H., Peschke D. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J. Pineal Res. 29:2000;201-208.
8. Burkhard C., Kelly J.P., Lim Y.H., Filley C.M., Parker W.D.J. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33:1993;512-517.
9. Cadet J.L., Lohr J.B., Jeste D.V. Free radicals and tardive dyskinesia. Trends Neurosci. 9:1986;107-108.
10. Cadet J.L., Lohr J.B., Jeste D.V. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals. Henn F.A., DeLisi L.E. Hand book of schizophrenia: the neurochemistry and pharmacology of schizophrenia. 1987;425-438 Elsevier, Amsterdam.
11. Cagnoli C.M., Atabay C., Kharlamova H., Mano H. Melatonin protects neurons from singlet oxygen-induced apoptosis. J. Pineal Res. 18:1995;222-226.
12. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry. 61:2000;5-9.
13. Cazevieille C., Safa R., Osborne N.N. Melatonin protects primary cultures of rat neurons from NMDA excitotoxicity and hypoxia/reoxygenation. Brain Res. 12:1997;120-124.
14. Cohen G., Spina M.B. Hydrogen production in neurons: implications for understanding Parkinson's disease. Hefti F., Weiner W.J. Progress in Parkinson's research. 1988;119-126 Plenum, New York.
15. Cohen G., Zubenko G.S. In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain. Psychopharmacology. 86:1985;365-368.
16. Coyle J.T., Puttfarcken P. Oxidative stress glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
17. Creese G., Burt D., Synder S.I.L. Dopamine receptor binding and pharmacological potencies and antischizophrenic drugs. Science. 192:1976;481-483.
18. Cuzzocrea S., Zigarelli B., Gilad E., Hake P., Salman A.L., Szabo C. Protective effect of melatonin in carrageenan-induced model of local inflammation. J. Pineal Res. 23:1997;106-116.
19. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr. Bull. 23:1997;583-609.
20. Elkashef A.M., Wyatt R.J. Tardive dyskinesia: possible involvement of free radical and treatment with vitamin E. Schrizophr. Bull. 25:1999;731-740.
21. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1959;70-77.
22. Escames G., Guerrero J.M., Reiter R.J., Garcia J.J., Munoz-Hoyos A., Ortiz G.G.et al. Melatonin and vitamin E limit nitric oxide-induced lipid peroxidation in rat brain homogenates. Neurosci. Lett. 230:1997;147-150.
23. Fleckenstein A.E., Metzger R.R., Beyeler M.L., Gibb J.W., Hanson G.R. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur. J. Pharmacol. 334:1997;111-114.
24. Galili R., Mosberg, Gil-Ad I., Weizman A., Melamed E., Offen D. Haloperidol-induced neurotoxicity - possible implications for tardive dyskinesia. J. Neural Transm. 107:2000;479-490.
25. Gepdiremen A., Duzenli S., Hacimuftuoglu A., Bulucu D., Suleyman H. The effects of melatonin in glutamate-induced neurotoxicity of rat cerebellar granular cell culture. Jpn. J. Pharmacol. 84:2000;467-469.
26. Gitto E., Tan D.X., Reiter R.J., Karbownik M., Manchester L.C., Cuzzocrea S.et al. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J. Pharm. Pharmacol. 53:2001;1393-1401.
27. Gorrod J.W., Fang J. On the metabolism of haloperidol. Xenobiotica. 23:1993;495-508.
28. Gupta S., Mosnik D., Black D.W., Berry S., Masand P.S. Tardive dyskinesia: review of treatments past, present, and future. Ann. Clin. Psychiatry. 11:1999;257-266.
29. Iacovitti L., Stull N.D., Johnstom K. Melatonin rescues dopamine neurons form cell death in tissue culture models of oxidative stress. Brain Res. 768:1997;317-326.
30. Kabuto H., Yokoi I., Ogawa N. Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation. Epilepsia. 39:1998;237-243.
31. Kim Y.S., Joo W.S., Jin B.K., Cho Y.H., Baik H.H., Park C.W. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. NeuroReport. 9:1998;2387-2390.
32. Kolter M., Rodriques C., Sainz R.M., Antolin I., Menendez-Pelaes A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J. Pineal Res. 24:1998;83-89.
33. Kono Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 186:1978;189-195.
34. Kulkarni S.K., Naidu P.S. Tardive dyskinesia: an update. Drugs Today. 37:2001;97-119.
35. Limson J., Nyokong T., Daya S. The interaction of melatonin and its precursors with aluminium, cadmium, copper, iron, lead and zinc: an adsorptive volumetric study. J. Pineal Res. 24:1998;15-21.
36. Lin A.M., Ho L.-T. Melatonin suppresses iron-induced neurodegeneration in rat brain. Free Radic. Biol. Med. 28:2000;904-911.
37. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin-Phenol reagent. J. Biol. Chem. 193:1951;265-275.
38. Luck H. Catalase. Bergmeyer H.U. Methods of enzymatic analysis. 1971;885-893 Academic Press, New York.
39. Melchiorri D., Reiter R.J., Sewerynek W., Chen L.D., Nistico G. Melatonin reduced kinate-induced lipid peroxidation in homogenates of different brain regions. FASEB J. 9:1995;1205-12010.
40. Miller J.W., Selhub J., Joseph J.A. Oxidative damage caused by free radicals produced during catecholamine autooxidation: protective effectives of O-methylation and melatonin. Free Radic. Biol. Med. 21:1996;241-249.
41. Naidu P.S., Kulkarni S.K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol. 428:2001;81-86.
42. Naidu P.S., Kulkarni S.K. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. Eur. J. Pharmacol. 430:2001;295-298.
43. Naidu P.S., Kulkarni S.K. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav. Pharmacol. 12:2001;209-216.
44. Nielsen E.B., Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology. 59:1978;85-89.
45. Ortiz G.G., Crespo-Lopez M.E., Moran-Moguel C., Garcia J.J., Reiter R.J., Acuna-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinology. 22:2001;101-108.
46. Pappolla M.A., Chyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J.et al. An assessment of the antioxidant and antiamyloidogenic properties of the melatonin: implications for Alzheimer's disease. J. Neural Transm. 107:2000;203-231.
47. Pieri C., Marra M., Moroni F., Recchioni R., Marchaselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 55:1994;PL271-PL276.
48. Pierrefiche G., Topall G., Courboin G., Henreit I., Labroit H. Antioxidant activity of melatonin in mice. Res. Commun. Chem. Pathol. Pharmacol. 80:1993;211-223.
49. Pozo D., Reiter R.J., Calvo J.R., Guerrero G.M. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J. Cell. Biochem. 65:1997;430-442.
50. Raveindranath V., Reed D.J. Glutathione depletion and formation of glutathione protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem. Biophys. Res. Commun. 169:1990;150-158.
51. Reiter R.J. Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocr. Rev. 12:1991;151-180.
52. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56:1998;359-384.
53. Reiter R.J. Melatonin: lowering the high price of free radicals. News Physiol. Sci. 15:2000;246-250.
54. Reiter R.J., Tang L., Garcia J.J., Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical physiology. Life Sci. 60:1997;2255-2271.
55. Reiter R.J., Tan D.X., Acuna-Castroviejo D., Burkhardt S., Karbownik M. Melatonin: mechanisms and actions as an antioxidant. Curr. Top. Biophys. 24:2000;171-183.
56. Reiter R.J., Tan D.X., Manchester L.C., Qi W. Biochemical reactivity of melatonin with reactive oxygen species and nitrogen species. Cell Biochem. Biophys. 34:2001;237-256.
57. Richardson M.A., Haugland G., Pass R., Craig T.J. The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacol. Bull. 22:1986;243-249.
58. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71:1998;1002-1012.
59. Sasaki H., Hashimoto K., Maeda Y., Inada T., Kitao Y., Fukui S.et al. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci. 56:1995;443-447.
60. Schulz J.B., Henshaw D.R., Siwek D., Jenkins B.G., Ferrante R.J., Ciplloni P.B.et al. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 64:1995;2239-2247.
61. Sewerynek E., Melchiorri D., Reiter R.J., Ortiz G.G., Lewinski A. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur. J. Pharmacol. 293:1995;327-334.
62. 2-induced lipid peroxidation in rat brain homogenates is greatly reduced by melatonin. Neurosci. Lett. 195:1995;203-205.
63. Sewerynek E., Melchiorri D., Chen L.D., Reiter R.J. Melatonin reduces both basal and lipopolysaccharide-induced lipid peroxidation. Free Radic. Biol. Med. 19:1995;903-909.
64. Shamir E., Barak Y., Plopsky I., Zisapel N., Elizur A., Weizman A. Is melatonin treatment effective for tardive dyskinesia? J. Clin. Psychiatry. 61:2000;556-558.
65. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N. Melatonin treatment for tardive dyskinesia. Arch. Gen. Psychiatry. 58:2001;1049-1052.
66. Shivakumar B.R., Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J. Pharmacol. Exp. Ther. 265:1993;1137-1141.
67. Soares K.V., Mcgrath J.J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2:2000;. [CD000209].
68. Tan D.X., Chen L.-D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin a potent endogenous hydroxyl radical scavenger. Endocr. J. 1:1993;57-60.
69. Tan D.X., Manchester L.C., Reiter R.L., Plummer B.F., Hardies L.J., Weintraub S.T.et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of melatonin interaction with hydroxyl radicals. Biochem. Biophys. Res. Commun. 253:1998;614-620.
70. Tan D.X., Manchester L.C., Reiter R.L., Plummer B.F., Limson J., Weintraub S.T.et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic. Biol. Med. 29:2000;1117-1185.
71. Urata Y., Honam S., Goto S., Tadoroki S., Ueda T., Cho S.et al. Melatonin induces γ-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med. 27:1999;838-847.
72. Vairetti M., Feletti F., Battaglia A., Pamparana F., Canonico P.L., Richelmi P.et al. Haloperidol-induced changes in glutathione and energy metabolism effect of nicergolin. Eur. J. Pharmacol. 367:1999;67-72.
73. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 99:1966;667-676.
74. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role of neurotoxicity and tardive dyskinesia. Brain Res. 788:1998;215-222.
75. Zispel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. 246:1982;161-163.